Recommended

Novo Nordisk bids $6.5bn for Metsera Therapeutics
MHRA to streamline UK rare disease drug regulatory pathway
Lilly invests €2.6bn in Netherlands manufacturing facility
MHRA recruits first Chief Medical and Scientific Officer
Galapagos to exit cell therapy business
Chiesi expands French metered dose inhaler facility
CPHI Milan to add AI zone for 2026
Hovione invests $100m in US spray drying manufacturing
news

Scottish Medicines Consortium approves Kymriah® CAR-T therapy

2
SHARES

The Kymriah (tisagenlecleucel) treatment has received a positive appraisal from the Scottish Medicines Consortium, after EMA approval last year.

The Scottish Medicines Consortium (SMC) has granted a positive appraisal to Kymriah® (tisagenlecleucel), a chimeric antigen receptor T-cell (CAR-T) therapy. The treatment is indicated for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who did not respond to two or more previous systemic treatments.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

The decision was based on the results for the ongoing multi-centre, global registration JULIET clinical trial. It will be the first CAR-T therapy fully reimbursed for eligible UK patients on the UK National Health Service (NHS).

The CAR-T therapy uses each individual patient’s cells for their cancer treatment. T cells are drawn from the patient’s blood and reprogrammed in the laboratory to create T cells that are genetically coded to recognise and fight the tumour cells in the patient.

Last year, the European Medicines Agency (EMA) granted Novartis, which produces the treatment, approval for tisagenlecleucel’s use in the EU.

It will be the first CAR-T therapy fully reimbursed for eligible UK patients on the UK National Health Service (NHS)”

“Just over a year ago, CAR-T therapy wasn’t available in the UK or anywhere in Europe. Today’s positive appraisal by the Scottish Medicines Consortium represents a milestone as now all eligible patients across the UK can access Kymriah on the NHS regardless of indication or geography,” said Mari Scheiffele, Novartis Oncology General Manager, UK & Ireland.

Share via
Share via